The first drug combinations have now reached Phase III clinical trials, including the phentermine–topiramate (Qnexa), the bupropion–zonisamide (Empatic®, Orexigen Therapeutics) and the ...

Naltrexone-bupropion is the most cost-effective, while phentermine-topiramate shows moderate viability. Price reductions of 30.5% for tirzepatide and 81.9% for semaglutide are needed to meet cost ...

Compared with lifestyle modification alone, all four medications assessed in the study -- including phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave) -- increased life expectancy ...

Naltrexone-bupropion and phentermine-topiramate are more cost-effective, offering savings due to lower treatment costs. Price reductions for antiobesity medications are crucial for equitable ...

The episode will feature John Amos, Chief Executive Officer at VIVUS LLC, along with leading weight-loss experts, to discuss QSYMIA ® (phentermine and topiramate extended-release capsules CIV ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

QSYMIA may slow the increase in height in children 12 years and older. QSIVA (phentermine and topiramate modified-release) hard capsules is contraindicated in pregnancy and in women of ...